Cyclic versus hemi-bastadins. Pleiotropic anti-cancer effects: From apoptosis to anti-angiogenic and anti-migratory effects

Molecules

Volumn 18, Issue 3, 2013, Pages 3543-3561

  Mathieu, Véronique ^a   Wauthoz, Nathalie ^a   Lefranc, Florence ^b   Niemann, Hendrik ^c   Amighi, Karim ^a   Kiss, Robert ^a   Proksch, Peter ^c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Angiogenesis; Apoptosis; Bastadins; Cancer; Hemibastadins

Indexed keywords

ANGIOGENESIS INHIBITOR; BASTADIN 16; BASTADIN 6; BASTADIN 9; DIPHENYL ETHER DERIVATIVE; SERUM ALBUMIN; PROTEIN BINDING;

ANIMAL; APOPTOSIS; ARTICLE; C57BL MOUSE; CANCER TRANSPLANTATION; CELL MOTION; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MELANOMA; FEMALE; HUMAN; IC 50; LUNG TUMOR; METASTASIS; MOUSE; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; SPONGE (PORIFERA); TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; DRUG EFFECTS; IC50; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; SECONDARY;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HALOGENATED DIPHENYL ETHERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PORIFERA; PROTEIN BINDING; SERUM ALBUMIN;

EID: 84875605061     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18033543     Document Type: Article

References (49)

1. Kazlauskas, R.; Lidgard, R.O.; Murphy, P.T.; Well, R.J. Brominated tyrosine-derived metabolites from the sponge Ianthella basta. Tetrahedron Lett. 1980, 21, 2277-2280.
2. Kazlauskas, R.; Lidgard, R.O.; Murphy, P.T.; Well, R.J.; Blount, J.F. Brominated tyrosine-derived metabolites from the sponge Ianthella basta. Aust. J. Chem. 1981, 34, 765-786.
3. Park, S.K.; Park, H.; Scheuer, P.J. Isolation and structure determination of a new bastadins from the marine sponge Ianthella basta. Bull. Korean Chem. Soc. 1994, 15, 534-537.
4. Pettit, G.R.; Butler, M.S.; Bass, C.G.; Doubek, D.L.; Williams, M.D.; Schmidt, J.M.; Pettit, R.K.; Hooper, J.N.; Tackett, L.P.; Filiatrault, M.J. Antineoplastic agents, 326. The stereochemistry of bastadins 8, 10, and 12 from the Bismarck archipelago marine sponge Ianthella basta. J. Nat. Prod. 1995, 58, 680-688.
5. Coll, J.C.; Kearns, P.S.; Rideout, J.A.; Sankar, V. Bastadin 21, a novel isobastarane metabolite from the Great Barrier Reef marine sponge Ianthella quadrangulata. J. Nat. Prod. 2002, 65, 753-756.
6. Calcul, L.; Inman, W.D.; Morris, A.A.; Tenney, K.; Ratman, J.; McKerrow, J.H.; Valeriote, F.A.; Crews, P. Additional insights on the bastadins: Isolation of analogues from the sponge Ianthella cf. reticulata and exploration of the oxime configurations. J. Nat. Prod. 2010, 73, 365-372.
7. Carroll, A.R.; Kaiser, S.M.; Davis, R.A.; Moni, R.W.; Hooper, J.N.; Quinn, R.J. A bastadins with potent and selective delta-opioid receptor binding affinity from the Australian sponge Ianthella flabelliformis. J. Nat. Prod. 2010, 73, 1173-1176.
8. Couladouros, E.A.; Pitsinos, E.N.; Moutsos, V.I.; Sarakinos, G. A general method for the synthesis of bastaranes and isobastaranes: First total synthesis of bastadins 5, 10, 12, 16, 20, and 21. Chemistry 2004, 11, 406-421.
9. Masuno, M.N.; Pessah, I.N.; Olmstead, M.M.; Molinski, T.F. Simplified cyclic analogues of bastadins-5. Structure-activity relationships for modulation of the Ryr1/FKBP12 Ca2+ channel complex. J. Med. Chem. 2006, 49, 4497-4511.
10. Zieminska, E.; Lazarewicz, JW.; Couladouros, E.A.; Moutsos, V.I.; Pitsinos, E.N. Open-chain half-bastadins mimic the effects of cyclic bastadins and calcium homeostasis in cultured neurons. Bioorg. Med. Chem. Lett. 2008, 18, 5734-5737.
11. Ortlepp, S.; Sjögren, M.; Dahlström, M.; Weber, H.; Ebel, R.; Edrada, R.; Thoms, C.; Schupp, P.; Bohlin, L.; Proksch, P. Antifouling activity of bromotyrosine-derived sponge metabolites and synthetic analogues. Mar. Biotechnol. 2007, 9, 776-785.
12. Bayer, M.; Hellio, C.; Maréchal, J.P.; Frank, W.; Lin, W.; Weber, H.; Proksch, P. Antifouling bastadins congeners target mussel phenoloxidase and complex copper(II) ions. Mar. Biotechnol. 2011, 13, 1148-1158.
13. Chen, L.; Molinski, T.F.; Pessah, I.N. Bastadin 10 stabilizes the open conformation of the ryanodinesensitive Ca2+ channel in an FKBP12-dependent manner. J. Biol. Chem. 1999, 274, 32603-32612.
14. Masuno, M.N.; Hoepker, A.C.; Pessah, I.N.; Molinski, T.F. 1-O-Sulfatobastadins-1 and -2 from Lanthella basta (Pallas). Antagonists of the RyR1-FKBP12 Ca2+ channel. Mar. Drugs 2004, 2, 176-184.
15. Zieminska, E.; Stafiej, A.; Pitsinos, E.N.; Couladouros, E.A.; Moutsos, V.; Kozlowska, H.; Toczylowska, B.; Lazarewicz, J.W. Synthetic bastadins modify the activity of ryanodine receptors in cultured cerebellar granule cells. Neurosignals 2006, 15, 283-292.
16. Reddy, A.V.; Ravinder, K.; Narasimhulu, M.; Sridevi, A.; Satyanarayana, N.; Kondapi, A.K.; Venkateswarlu, Y. New anticancer bastadins alkaloids from the sponge Dendrilla cactos. Bioorg. Med. Chem. 2006, 14, 4452-4457.
17. Greve, H.; Kehraus, S.; Krick, A.; Kelter, G.; Maier, A.; Fiebig, H.H.; Wright, A.D.; König, G.M. Cytotoxic bastadin 24 from the Australian sponge Ianthella quadrangulata. J. Nat. Prod. 2008, 71, 309-312.
18. Kotoku, N.; Tsujita, H.; Hiramatsu, A.; Mori, C.; Koizumi, N.; Kobayashi, M. Efficient total synthesis of bastadins 6, an anti-angiogenic brominated tyrosine-derived metabolite from marine sponge. Tetrahedron 2005, 61, 7211-7218.
19. Kotoku, N.; Hiramatsu, A.; Tsujita, H.; Hirakawa, Y.; Sanagawa, M.; Aoki, S.; Kobayashi, M. Structure-activity relationship study of bastadins 6, an anti-angiogenic brominated-tyrosine derived metabolite from marine sponge. Arch. Pharm. 2008, 341, 568-577.
20. Aoki, S.; Cho, S.H.; Hiramatsu, A.; Kotoku, N.; Kobayashi, M. Bastadins, Cyclic tetramers of brominated-tyrosine derivatives, Selectively inhibit the proliferation of endothelial cells. J. Nat. Med. 2006, 60, 231-235.
21. Aoki, S.; Cho, S.H.; Ono, M.; Kuwano, T.; Nakao, S.; Kuwano, M.; Nakagawa, S.; Gao, J.Q.; Mayumi, T.; Shibuya, M.; Kobayashi, M. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs 2006, 17, 269-278.
22. Chen, K.G.; Sikic, B.I. Molecular pathways: Regulation and therapeutic implications of multidrug resistance. Clin. Cancer Res. 2012, 18, 1863-1869.
23. Lefranc, F.; Sadeghi, N.; Camby, I.; Metens, T.; De Witte, O.; Kiss, R. Present and potential future issues in glioblastoma treatment. Expert Rev. Anticancer Ther. 2006, 6, 719-732.
24. Maira, F.; Catania, A.; Candido, S.; Russo, A.E.; McCubrey, J.A.; Libra, M.; Malaponte, G.; Fenga, C. Molecular targeted therapy in melanoma: A way to reverse resistance to conventional drugs. Curr. Drug Deliv. 2012, 9, 17-29.
25. Fennell, D.A.; Swanton, C. Unlocking Pandora's box: personalizing cancer cell death in non-small cell lung cancer. EPMA J. 2012, 3, 6.
26. Bruyère, C.; Lonez, C.; Duray, A.; Cludts, S.; Ruysschaert, J.M.; Saussez, S.; Yeaton, P.; Kiss, R.; Mijatovic, T. Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer 2011, 117, 2004-2016.
27. Nagaprashantha, L.; Vartak, N.; Awasthi, S.; Awasthi, S.; Singhal, S.S. Novel anti-cancer compounds for developing combinatorial therapies to target anoïkis-resistant tumors. Pharm. Res. 2012, 29, 621-636.
28. Okayama, H. Cell cycle control by anchorage signaling. Cell Signal. 2012, 24, 1599-1609.
29. Mathieu, V.; Mijatovic, T.; Van Damme, M.; Kiss, R. Gastrin exerts pleitropic effects on human melanoma cell biology. Neoplasia 2005, 7, 930-943.
30. Mégalizzi, V.; Mathieu, V.; Mijatovic, T.; Gailly, P.; Debeir, O.; De Neve, N.; Van Damme, M.; Bontempi, G.; Haibe-Kains, B.; Decaestecker, C.; et al. 4-IBP, A sigma1 receptor agonist, Decreases the migration of human cancer cells, Including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 2007, 9, 358-369.
31. Tabatabai, G.; Tonn, J.C.; Stupp, R.; Weller, M. The role of integrins in glioma biology and anti-glioma therapies. Curr. Pharm. Des. 2011, 17, 2402-2410.
32. Svensen, N.; Walton, J.G.; Bradley, M. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 2012, 33, 186-192.
33. Mathieu, A.; Remmelink, M.; D'Haene, N.; Penant, S.; Gaussin, J.F.; Van Ginckel, R.; Darro, F.; Kiss, R.; Salmon, I. Development of a chemoresistant orthotopic human non-small cell lung carcinoma models in nude mice: Analyses of tumor heterogeneity in relation to the immunohistochemical levels of expression of ciclooxygenase-2, ornitine decarboxylase, lung-related resistance protein, prostaglandine-E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer 2004, 101, 1908-1918.
34. Van Goietsenoven, G.; Hutton, J.; Becker, J.P.; Lallemand, B.; Robert, F.; Lefranc, F.; Pirker, C.; Vandenbussche, G.; Van Antwerpen, P.; Evidente, A.; et al. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010, 24, 4575-4584.
35. Ingrassia, L.; Lefranc, F.; Dewelle, J.; Pottier, L.; Mathieu, V.; Spiegl-Kreinecker, S.; Sauvage, S.; El Yazidi, M.; Dehoux, M.; Berger, W.; et al. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J. Med. Chem. 2009, 52, 1100-1104.
36. Dumont, P.; Ingrassia, L.; Rouzeau, S.; Ribaucour, F.; Thomas, S.; Roland, I.; Darro, F.; Lefranc, F.; Kiss, R. The amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 2007, 9, 766-776.
37. Goffin, E.; Lamoral-Theys, D.; Tajedinne, N.; de Tullio, P.; Mondin, L.; Lefranc, F.; Gailly, P.; Rogister, B.; Kiss, R.; Pirotte, B. N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure-activity relationship analysis. Eur. J. Med. Chem. 2012, 54, 834-844.
38. Lallemand, B.; Masi, M.; Maddau, L.; De Lorenzi, M.; Dam, R.; Cimmino, A.; Moreno Y Banuls, L.; Andolfi, A.; Kiss, R.; Mathieu, V.; et al. Evaluation of in vitro anticancer activity of sphaeropsidins A-C, fungal rearranged pimarane diterpenes, and semisynthetic derivatives. Phytochem. Lett. 2012, 5, 770-775.
39. Delbrouck, C.; Doyen, I.; Belot, N.; Decaestecker, C.; Ghanooni, R.; de Lavareille, A.; Kaltner, H.; Choufani, G.; Danguy, A.; Vandenhoven, G.; et al. Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab. Invest. 2002, 82, 147-158.
40. Guzman, R.E.; Bolanos, P.; Delgado, A.; Rojas, H.; DiPolo, R.; Caputo, C.; Jaffe, E.H. Depolymerization and rearrangement of actin filaments during exocytosis in rat peritoneal mast cells: involvement of ryanodine-sensitive calcium stores. Pflugers Arch. 2007, 454, 131-141.
41. Bose, D.D.; Thomas, D.W. The actin cytoskeleton differentially regulates NG115-401L cell ryanodine receptor and inositol 1,4,5-triphosphate receptor induced calcium signaling pathways. Biochem. Biophys. Res. Commun. 2009, 379, 594-599.
42. Lefranc, F.; Mijatovic, T.; Mathieu, V.; Rorive, S.; Decaestecker, C.; Debeir, O.; Brotchi, J.; Van Ham, P.; Salmon, I.; Kiss, R. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin. Cancer Res. 2004, 10, 8250-8265.
43. Mackrill, J.J. Ryanodine receptor calcium channels and their partners as drug targets. Biochem. Pharmacol. 2010, 79, 1535-1543.
44. Mathieu, V.; Le Mercier, M.; De Neve, N.; Sauvage, S.; Gras, T.; Roland, I.; Lefranc, F.; Kiss, R. Galectin-1 knockdown increases sensitivity to temozlomide in a B16F10 mouse metastatic melanoma model. J. Invest. Dermatol. 2007, 127, 2399-2410.
45. Wauthoz, N.; Deleuze, P.; Hecq, J.; Roland, I.; Saussez, S.; Adanja, I.; Debeir, O.; Decaestecker, C.; Mathieu, V.; Kiss, R.; et al. In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur. J. Pharm. Sci. 2010, 39, 402-411.
46. Wauthoz, N.; Deleuze, P.; Saumet, A.; Duret, C.; Kiss, R.; Amighi, K. Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment. Pharm. Res. 2011, 28, 762-775.
47. Black, A.; Morris, D. Personalized medicine in metastatic non-small-cell lung cancer: Promising targets and current clinical trials. Curr. Oncol. 2012, 19, S73-S85.
48. Ganguli, A.; Wiegand, P.; Gao, X.; Carter, J.A.; Botterman, M.F.; Ray, S. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: A systematic review. Qual. Life Res. 2012, in press.
49. Nakata, A.; Gotoh, N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin. Ther. Targets 2012, 16, 771-781.